Supreme Court temporarily restores telehealth access to mifepristone amid ongoing legal fight
The Supreme Court on Thursday reversed a 5th Circuit order and allowed mifepristone to be prescribed and mailed through telehealth for the time being.
The reversal follows a lawsuit brought by Louisiana, which argues that remote prescribing undermines the state’s strict abortion ban. The lower court had reinstated the former REMS restrictions that the FDA lifted in 2021.
The decision does not end the legal fight, and the case will continue through the courts. In the meantime, demand for telehealth medication abortions has risen sharply since the 2022 overturn of Roe v. Wade.
Studies cited in the article show that telehealth delivery of the two‑drug regimen remains effective, and providers are preparing backup plans in case future rulings reimpose restrictions.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “Opinion: Telehealth abortion with mifepristone continues, with backup plans still in place”
read at STAT ↗
comments(0)
5-min edit window · permanent after that